Nifedipine Tablet, Film Coated, Extended Release
Product Images NDC 0904-7081

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Nifedipine (NDC 0904-7081). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

0b564dde 2149 4f5c 900b 301a95138a61 00

Nifedipine Extended-Release Tablets, USP 90 mg unit dose by Major Pharmaceuticals. The label includes product strength, quantity of 30 tablets, prescription only status, dosing information, storage instructions, and distributor details for Ingenus Pharmaceuticals and Major Pharmaceuticals.*

FDA Label Image

0b564dde 2149 4f5c 900b 301a95138a61 01

Nifedipine Extended-Release Tablets, USP 60 mg unit dose blister card by Major Pharmaceuticals. The label shows the proprietary name, strength, dosage form, and quantity of 100 tablets. It includes prescription-only designation and directions for use and storage instructions on the back panel.*

FDA Label Image

0b564dde 2149 4f5c 900b 301a95138a61 02

Nifedipine Extended-Release Tablets, USP 30 mg unit dose packaging label by Major Pharmaceuticals. The label includes the NDC 0904-7080-61 and indicates the product contains 100 tablets. It describes the dosage form as extended-release film-coated tablets and provides storage instructions, distributor information, and safety warnings.*

FDA Label Image

01 (Image 01)

Chemical structure of the active ingredient nifedipine depicted as a molecular diagram with labeled functional groups and bonds.*

FDA Label Image

02 (Image 02)

A data table comparing the percentage of reported adverse effects including headache, fatigue, dizziness, constipation, and nausea between two groups: Nifedipine extended-release tablets (N=707) and placebo (N=266). The table shows higher percentages for adverse effects generally in the Nifedipine group compared to placebo.*

FDA Label Image

03 (Image 03)

Data table showing the percentages of various adverse effects reported in a study comparing Nifedipine Capsules and placebo groups. The table lists effects such as dizziness, flushing, headache, weakness, and others, with corresponding percentage values for each group.*

FDA Label Image

04 (Image 04)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.